AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27459236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐led care program (comprehensive geriatric assessment, evidence‐based care planning, care coordination, and follow‐up)
Number of subjects: 3092
Study 27459236 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3092
Study 25594611 — intervention group
Group type: COMPARATOR
Intervention: tanezumab 20 mg
Number of subjects: 0
Study 25594611 — intervention group
Group type: COMPARATOR
Intervention: tanezumab 50 μg/kg
Number of subjects: 0
Study 25594611 — intervention group
Group type: COMPARATOR
Intervention: tanezumab 200 μg/kg
Number of subjects: 0
Study 25594611 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 24391768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 1335
Study 20736471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 86
Study 20736471 — intervention group
Group type: COMPARATOR
Intervention: Relaxation with educational support
Number of subjects: 86
Study 18436090 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis regimen (4 hours 3 times weekly)
Number of subjects: 18
Study 18436090 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 hours of hemodialysis
Number of subjects: 18
Study 18436090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis with increased dialysate flow
Number of subjects: 18
Study 18436090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis with 2 dialyzers in parallel
Number of subjects: 18
Study 15902180 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end repair
Number of subjects: 41
Study 15902180 — intervention group
Group type: COMPARATOR
Intervention: Overlapping repair
Number of subjects: 41
Study 12507780 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 12507780 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 10930964 — intervention group
Group type: EXPERIMENTAL
Intervention: Elixir (30-40 mg kg-1)
Number of subjects: 30
Study 10930964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogelatin capsule suppository (30-40 mg kg-1)
Number of subjects: 30
Study 10930964 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride base suppository (30-40 mg kg-1)
Number of subjects: 30
Study 10930964 — intervention group
Group type: COMPARATOR
Intervention: Elixir
Number of subjects: 30
Study 8664843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aero-bars (AB)
Number of subjects: 11
Study 8664843 — intervention group
Group type: COMPARATOR
Intervention: Brake hoods (BH)
Number of subjects: 11
Study 1994118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine users
Number of subjects: 224
Study 1994118 — intervention group
Group type: COMPARATOR
Intervention: No recent cocaine use
Number of subjects: 224
Study 6527524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 km jogging
Number of subjects: 40
Study 6527524 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 km jogging
Number of subjects: 40
Study 6527524 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 km jogging
Number of subjects: 40
Study 6527524 — intervention group
Group type: COMPARATOR
Intervention: Non-jogging (control)
Number of subjects: 40
Study 31648910 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine at 6 months interval
Number of subjects: 0
Study 29580537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ultrasound (US) and high-pressure homogenization (HPH)
Number of subjects: 0
Study 29580537 — intervention group
Group type: COMPARATOR
Intervention: High-pressure homogenization (HPH)
Number of subjects: 0
Study 29580537 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US)
Number of subjects: 0
Study 26608718 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 70
Study 26608718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24522201 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine MR with 10 mg rifampicin
Number of subjects: 24
Study 24522201 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine MR with 20 mg rifampicin
Number of subjects: 24
Study 24522201 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine MR with 100 mg rifampicin
Number of subjects: 24
Study 24522201 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam clearance
Number of subjects: 24
Study 24522201 — intervention group
Group type: EXPERIMENTAL
Intervention: 4β-hydroxycholesterol/cholesterol ratio
Number of subjects: 24
Study 22314455 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 22314455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Number of subjects: 60
Study 20100142 — intervention group
Group type: EXPERIMENTAL
Intervention: IM‐MS irradiation
Number of subjects: 3866
Study 20100142 — intervention group
Group type: COMPARATOR
Intervention: Control (no IM‐MS irradiation)
Number of subjects: 3866
Study 17617944 — intervention group
Group type: EXPERIMENTAL
Intervention: LC1 fermented milk (373 kJ (89 kcal)/d)
Number of subjects: 24
Study 17617944 — intervention group
Group type: COMPARATOR
Intervention: Control group (373 kJ/d of the same EN)
Number of subjects: 24
Study 15139942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled-analgesia
Number of subjects: 125
Study 15139942 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 125
Study 11813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with a higher volume of water (10 x 3 mL)
Number of subjects: 21
Study 11813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with a lower volume of water (5 mL)
Number of subjects: 21
Study 11813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing duration of 10 seconds
Number of subjects: 21
Study 11813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing duration of 60 seconds
Number of subjects: 21
Study 9601831 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold TENS (frequency 35 Hz, pulse width 100 milliseconds, modulation 50%)
Number of subjects: 10
Study 9601831 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 10
Study 7995001 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ketoconazole
Number of subjects: 9
Study 7995001 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole
Number of subjects: 9
Study 7995001 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (control phase)
Number of subjects: 9
Study 2691002 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% glucose + glucose polymer (group G + GP)
Number of subjects: 18
Study 2691002 — intervention group
Group type: COMPARATOR
Intervention: 2.5% glucose (group G)
Number of subjects: 18
Study 812895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium powder, 20 mg three times daily
Number of subjects: 26
Study 812895 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 26
Study 812895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium powder
Number of subjects: 26
Study 31713269 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICK-STOP stopping rule applied to randomized tests
Number of subjects: 0
Study 30865071 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser lash tilt technique
Number of subjects: 46
Study 30865071 — intervention group
Group type: COMPARATOR
Intervention: Upper eyelid blepharoplasty alone (control)
Number of subjects: 46
Study 30865071 — intervention group
Group type: COMPARATOR
Intervention: Comparison of laser lash group vs control group
Number of subjects: 46
Study 28954261 — intervention group
Group type: COMPARATOR
Intervention: Supervised Toothbrushing (STB)
Number of subjects: 120
Study 28954261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) with High-Viscosity Glass-Ionomer Cement (HVGIC) sealants
Number of subjects: 120
Study 28954261 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Resin (CR)
Number of subjects: 120
Study 26421970 — intervention group
Group type: EXPERIMENTAL
Intervention: Male version case histories
Number of subjects: 180
Study 26421970 — intervention group
Group type: EXPERIMENTAL
Intervention: Female version case histories
Number of subjects: 180
Study 26421970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonambiguous case histories
Number of subjects: 180
Study 26421970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous case histories
Number of subjects: 180
Study 24968210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desks (SSDs)
Number of subjects: 28
Study 22615291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet A (100 mg)
Number of subjects: 16
Study 22615291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet B (100 mg)
Number of subjects: 16
Study 22615291 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule (100 mg)
Number of subjects: 16
Study 22615291 — intervention group
Group type: COMPARATOR
Intervention: Oral suspension (control)
Number of subjects: 16
Study 22615291 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations of posaconazole (100 mg)
Number of subjects: 16
Study 19278796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 32
Study 17433383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision Restoration Therapy (VRT)
Number of subjects: 140
Study 17433383 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 140
Study 17433383 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-related hallucinations
Number of subjects: 140
Study 15333726 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention promoting adequate complementary feeding practices; health and nutrition workers trained to counsel on locally developed feeding recommendations.
Number of subjects: 1025
Study 15333726 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention promoting adequate complementary feeding practices.
Number of subjects: 1025
Study 15333726 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific feeding intervention.
Number of subjects: 1025
Study 12555626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 10 mg nitroglycerine patch (12 hours)
Number of subjects: 150
Study 12555626 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting oral 40 mg isosorbide-5-mononitrate (once a day)
Number of subjects: 150
Study 9792489 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise plus relaxation
Number of subjects: 76
Study 9792489 — intervention group
Group type: COMPARATOR
Intervention: exercise without relaxation
Number of subjects: 76
Study 7758297 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 1360
Study 7758297 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive life events
Number of subjects: 1360
Study 2195921 — intervention group
Group type: COMPARATOR
Intervention: Combination methylprednisolone and placebo troleandomycin
Number of subjects: 15
Study 2195921 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and troleandomycin (P-TAO)
Number of subjects: 15
Study 2195921 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone-TAO (MPn-TAO)
Number of subjects: 15
Study 2195921 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (250 mg once daily or every other day)
Number of subjects: 15
Study 2195921 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin
Number of subjects: 15
Study 2195921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TAO combined with MPn
Number of subjects: 15
Study 391624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine treatment
Number of subjects: 0
Study 391624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31896379 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731
Study 31896379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 731
Study 29951850 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (n = 18)
Number of subjects: 38
Study 29951850 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy (n = 20)
Number of subjects: 38
Study 28318365 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE) using Embosphere microspheres
Number of subjects: 128
Study 28318365 — intervention group
Group type: COMPARATOR
Intervention: Panhysterectomy
Number of subjects: 128
Study 28318365 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group for TGF-β levels)
Number of subjects: 128
Study 25491384 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic women
Number of subjects: 19
Study 25491384 — intervention group
Group type: COMPARATOR
Intervention: Non-allergic women
Number of subjects: 19
Study 25491384 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CCL22 mRNA expression in CBMC
Number of subjects: 19
Study 25491384 — intervention group
Group type: EXPERIMENTAL
Intervention: p35 expression in placenta
Number of subjects: 19
Study 25491384 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5 expression in PBMC
Number of subjects: 19
Study 24785602 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 143
Study 24785602 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 143
Study 23116646 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAR+MET+1-3×GLU (group 2)
Number of subjects: 476
Study 23116646 — intervention group
Group type: COMPARATOR
Intervention: GLAR+MET+3×GLU (group 1)
Number of subjects: 476
Study 23116646 — intervention group
Group type: COMPARATOR
Intervention: GLAR+MET+IS+1-3×GLU (group 3)
Number of subjects: 476
Study 19458319 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity CIMT
Number of subjects: 52
Study 19458319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-matched CIMT
Number of subjects: 52
Study 19458319 — intervention group
Group type: COMPARATOR
Intervention: Traditional UE therapy (Control)
Number of subjects: 52
Study 17877827 — intervention group
Group type: COMPARATOR
Intervention: Room temperature irrigation and intravenous fluids
Number of subjects: 120
Study 17877827 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid at 38 degrees C and room temperature intravenous fluid
Number of subjects: 120
Study 17877827 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid and warmed intravenous fluids at 38 degrees C
Number of subjects: 120
Study 14687858 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline (50‐200 mg/day)
Number of subjects: 239
Study 14687858 — intervention group
Group type: COMPARATOR
Intervention: imipramine (75‐225 mg/day)
Number of subjects: 239
Study 12109659 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-flow injection-rate method (group A)
Number of subjects: 240
Study 12109659 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection-rate method (group B)
Number of subjects: 240
Study 9433339 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 51
Study 9433339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8948688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (average daily dose, 21.5 mg/day) for 4 weeks
Number of subjects: 24
Study 8948688 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 24
Study 1632260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 micrograms b.i.d.
Number of subjects: 20
Study 1632260 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo b.i.d.
Number of subjects: 20
Study 79031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral linoleic-acid supplementation for 10 months
Number of subjects: 12
Study 79031 — intervention group
Group type: COMPARATOR
Intervention: Placebo lipid
Number of subjects: 12
Study 30934797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g PGX granules (PGXG)
Number of subjects: 120
Study 30934797 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g PolyGlycopleX softgel capsules (PGXS)
Number of subjects: 120
Study 30934797 — intervention group
Group type: COMPARATOR
Intervention: 5 g rice flour (RF)
Number of subjects: 120
Study 29556618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent hexylaminolevulinate photodynamic diagnosis (PDD)
Number of subjects: 113
Study 29556618 — intervention group
Group type: COMPARATOR
Intervention: Standard white-light cystoscopy (WLC)
Number of subjects: 113
Study 26070406 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir plus ritonavir (200/100 mg), ombitasvir (25 mg), and dasabuvir (400 mg)
Number of subjects: 24
Study 24107882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study 21806904 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during dental treatment
Number of subjects: 90
Study 21806904 — intervention group
Group type: COMPARATOR
Intervention: No parental presence during dental treatment
Number of subjects: 90
Study 19014944 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 1256
Study 19014944 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging
Number of subjects: 1256
Study 16505424 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time between the first day of chemotherapy and the last day of chest radiation (SER)
Number of subjects: 0
Study 16505424 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter SER
Number of subjects: 0
Study 16505424 — intervention group
Group type: EXPERIMENTAL
Intervention: Each week of extension of the SER beyond the shortest SER arm
Number of subjects: 0
Study 17145253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg, sustained-release)
Number of subjects: 248
Study 17145253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 12689614 — intervention group
Group type: EXPERIMENTAL
Intervention: FR+ Stress Group (familial risk)
Number of subjects: 53
Study 12689614 — intervention group
Group type: EXPERIMENTAL
Intervention: FR‐ Stress Group (normal risk)
Number of subjects: 53
Study 12689614 — intervention group
Group type: COMPARATOR
Intervention: FR‐ Control Group (normal risk, no stress)
Number of subjects: 53
Study 9884376 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 317
Study 9884376 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins
Number of subjects: 317
Study 9884376 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 317
Study 9884376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 8905472 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms po at 0 min) before and after testosterone replacement (250 mg i.m. every 21 days)
Number of subjects: 14
Study 8905472 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms po at 0 min) before and after testosterone replacement
Number of subjects: 14
Study 8905472 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms po at 0 min)
Number of subjects: 14
Study 1713132 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 38
Study 1713132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6344041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 0
Study 6344041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 0
Study 6344041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 0
Study 6344041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 0
Study 6344041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1300 mg
Number of subjects: 0
Study 6344041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29521681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 41
Study 29521681 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 41
Study 27632641 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year foot abduction bracing
Number of subjects: 139
Study 27632641 — intervention group
Group type: COMPARATOR
Intervention: 4-year foot abduction bracing
Number of subjects: 139
Study 25075811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower awareness rating at 12 months
Number of subjects: 95
Study 25075811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower awareness rating at 36 months
Number of subjects: 95
Study 25075811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher awareness rating at 12 months
Number of subjects: 95
Study 25075811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher awareness rating at 36 months
Number of subjects: 95
Study 25075811 — intervention group
Group type: EXPERIMENTAL
Intervention: NPI-Q score increase for lower awareness at 36 months
Number of subjects: 95
Study 25075811 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score decline for lower awareness at 36 months
Number of subjects: 95
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3400 m altitude (first/second night) - males
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3400 m altitude (first/second night) - females
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5400 m altitude (first night) - males
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5400 m altitude (first night) - females
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5400 m altitude (after 10 days) - males
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5400 m altitude (after 10 days) - females
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3400 m altitude - males
Number of subjects: 37
Study 23294420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5400 m altitude - males
Number of subjects: 37